Zobrazeno 1 - 10
of 175
pro vyhledávání: '"Fotios V Michelis"'
Publikováno v:
eJHaem, Vol 4, Iss 1, Pp 269-272 (2023)
Abstract To date, allogenic stem cell transplant (ASCT) remains the only potential curative option for patients with primary myelofibrosis (PMF). However, relapse rates and associated mortality remain a concern. A second ASCT may not be feasible due
Externí odkaz:
https://doaj.org/article/48dac9ddf0794a52b5d7b765694ea41b
Autor:
Dennis D. H. Kim, Igor Novitzky Basso, Taehyung Simon Kim, Seong Yoon Yi, Kyoung Ha Kim, Tracy Murphy, Steven Chan, Mark Minden, Ivan Pasic, Wilson Lam, Arjun Law, Fotios V. Michelis, Armin Gerbitz, Auro Viswabandya, Jeffrey Lipton, Rajat Kumar, Stanley W. K. Ng, Tracy Stockley, Tong Zhang, Ian King, Jonas Mattsson, Jean C. Y. Wang
Publikováno v:
eJHaem, Vol 3, Iss 3, Pp 873-884 (2022)
Abstract A 17‐gene stemness (LSC17) score determines risk in acute myeloid leukaemia patients treated with standard chemotherapy regimens. The present study further analysed the impact of the LSC17 score at diagnosis on outcomes following allogenei
Externí odkaz:
https://doaj.org/article/369a826fb44c40558e7eed079916d481
Autor:
Kyoung Ha Kim, TaeHyung Kim, Igor Novitzky-Basso, Hyewon Lee, Youngseok Yoo, Jae-Sook Ahn, Ivan Pasic, Arjun Law, Wilson Lam, Fotios V. Michelis, Armin Gerbitz, Auro Viswabandya, Jeffrey Lipton, Rajat Kumar, Jonas Mattsson, Zhaolei Zhang, Nathali Kaushansky, Yardena Brilon, Noa Chapal-Ilani, Tamir Biezuner, Liran I Shlush, Dennis Dong Hwan Kim
Publikováno v:
Haematologica, Vol 108, Iss 7 (2023)
Donor clonal hematopoiesis may be transferred to the recipient through allogeneic hematopoietic stem cell transplantation (HSCT), but the potential for adverse long-term impact on transplant outcomes remains unknown. A total of 744 samples from 372 r
Externí odkaz:
https://doaj.org/article/63eae2c453294c49965bc79b50918746
Autor:
Eshrak Al-Shaibani, Shiyi Chen, Carol Chen, Ivan Pasic, Fotios V. Michelis, Wilson Lam, Arjun Law, Igor Novitzky-Basso, Armin Gerbitz, Dennis D. Kim, Auro Viswabandya, Jeffrey H. Lipton, Jonas Mattson, Rajat Kumar
Publikováno v:
Annals of Hematology. 102:917-926
Autor:
Ram Vasudevan Nampoothiri, Kenny Tang, Andre Schuh, Wilson Lam, Dawn Maze, Fotios V. Michelis, Steven Chan, Vikas Gupta, Dennis Kim, Rajat Kumar, Jeffrey Howard Lipton, Jonas Mattsson, Mark Minden, Aaron Schimmer, Hassan Sibai, Auro Viswabandya, Karen Yee, Tracy Murphy, Arjun D. Law
Publikováno v:
European Journal of Haematology. 110:618-625
Autor:
Ivan Pasic, Annie H. Ren, Ram Vasudevan Nampoothiri, Ioannis Prassas, Jeffrey H. Lipton, Jonas Mattsson, Eleftherios P. Diamandis, Fotios V. Michelis
Publikováno v:
Clinical Chemistry and Laboratory Medicine (CCLM). 61:1005-1014
Objectives Allogeneic hematopoietic cell transplantation (HCT) is associated with acute graft-vs.-host disease (aGVHD). The presented study applied a novel multiplex antibody-based proximity extension assay (PEA) proteomic platform that can detect th
Publikováno v:
eJHaem. 4:269-272
Autor:
Maria Queralt Salas, Abel Santos Carreira, Eshetu G. Atenafu, Tommy Alfaro Moya, Arjun D. Law, Wilson Lam, Ivan Pasic, Carol Chen, Dennis Dong Hwan Kim, Fotios V. Michelis, Armin Gerbitz, Jeffrey H. Lipton, Rajat Kumar, Jonas Mattsson, Auro Viswabandya
Publikováno v:
Blood. 140:7625-7627
Autor:
Auro Viswabandya, Jeffrey H. Lipton, Armin Gerbitz, Rhida Bautista, Arjun Datt Law, Dennis Dong Hwan Kim, Fotios V. Michelis, Wilson Lam, Ivan Pasic, Rajat Kumar, Jonas Mattsson, Eshrak Al-Shaibani, Zeyad Al-Shaibani
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:e327-e334
Background: Allogeneic hematopoietic cell transplantation (HCT) is potentially curative for hematological disease however can be complicated by relapse or graft failure (GF), for which second-HCT and donor lymphocyte infusions (DLI) are performed. Th
Autor:
Maria Queralt Salas, Arjun Datt Law, Wilson Lam, Zeyad Al-Shaibani, David Loach, Dennis (Dong Hwan) Kim, Fotios V. Michelis, Santhosh Thyagu, Rajat Kumar, Jeffrey Howard Lipton, Jonas Mattsson, Auro Viswabandya
Publikováno v:
Clinical Hematology International, Vol 1, Iss 2 (2019)
Haploidentical stem cell transplantation (haploSCT) has greatly improved access to curative treatment for myeloid malignancies in patients without suitable matched sibling/unrelated donors. We investigated the safety and efficacy of haploSCT after re
Externí odkaz:
https://doaj.org/article/d1fb35b8e0cd4c28aa1183db06145608